Title | A Blood Test for Alzheimer's Disease: It's about Time or Not Ready for Prime Time? |
Publication Type | Journal Article |
Year of Publication | 2022 |
Authors | Galasko, DR, Grill, JD, Lingler, JH, Heidebrink, JL |
Corporate Authors | Symptomatic Subcommittee of the Advisory Group on Risk Evidence Education for Dementia (AGREEDementia) |
Journal | J Alzheimers Dis |
Volume | 90 |
Issue | 3 |
Pagination | 963-966 |
Date Published | 2022 |
ISSN | 1875-8908 |
Keywords | Alzheimer Disease, Amyloid beta-Peptides, Biomarkers, Cognitive Dysfunction, Hematologic Tests, Humans, tau Proteins |
Abstract | A blood test for Alzheimer's disease is now available for clinical use in persons with cognitive impairment. This is an extraordinary milestone, though the amyloid-based PrecivityAD™ test is not without limitations. Pre and post-test counseling are essential. Phosphorylated tau blood tests are likely to follow soon. When used in conjunction with an appropriate clinical evaluation, blood tests provide the opportunity for an early, accurate, and accessible diagnosis of Alzheimer's disease. Standalone use, however, carries a significant risk of misinterpretation and is strongly discouraged. Now is the time to develop appropriate use criteria to guide the use of these promising assays. |
DOI | 10.3233/JAD-215490 |
Alternate Journal | J Alzheimers Dis |
PubMed ID | 35147543 |